Sign in
CompletedPhase 1

Mirtazapine and Methamphetamine Drug-drug Interaction Study

Key facts

Who runs it
San Francisco Department of Public Health
Where
Los Angeles and San Francisco, United StatesSee the 3 sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
15 people enrolled
Started
3 May 2021
Ended
31 May 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Mirtazapine
  • Methamphetamine
Record updated
27 September 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • English-speaking
  • age 18-55 years inclusive
  • meet DSM-V criteria for MA use disorder, as diagnosed via SCID
  • provide MA-positive urine during screening
  • have a resting heart rate of 50-90
  • have a systolic blood pressure ≤ of 100-150 mm Hg, and diastolic blood pressure of 45-90 Hg within two days prior to admission
  • have a baseline EKG that demonstrates normal sinus rhythm, QTc < 440 msec in men or QTc < 450 msec in women
  • have acceptable safety lab data, ALT / AST<3x upper limit nL; est GFR >50
  • if female (except females of non-childbearing potential-e.g., at least 1 year post-menopausal or surgically sterile), not pregnant confirmed by negative pregnancy test nor lactating and willing to use a medically approved method of birth control to prevent pregnancy during the trial and for 7 days after the last dose of study medication
  • For those who also use opioids and are on methadone maintenance treatment (Group 2), urine positive for methadone and negative for buprenorphine on admission

Who cannot take part

  • current ongoing treatment with psychotropic medications (e.g. antidepressants, antipsychotics, antiepileptics, sedative/hypnotics, narcotic analgesics)
  • urine positive for MA and other unplanned drugs on the day of admission and breathalyzer results negative for alcohol
  • any prior adverse reaction to MA; including chest pain or epileptic seizure
  • Have current cocaine, cannabis, or alcohol use disorder by DSM-V SCID
  • current or past history of seizure disorder
  • major psychiatric disorder not due to substance abuse (e.g., schizophrenia, bipolar illness but excepting stable major depressive disorder, generalized anxiety disorder, etc.) as assessed by the SCID
  • have a current neurological disorder (e.g., organic brain disease, dementia) or medical condition which would make study compliance difficult or compromise informed consent
  • history of suicide attempt(s) in the past 90 days or current suicidal intent or plan by SCID
  • evidence of untreated or unstable serious medical illness including: neuroendocrine, autoimmune, renal, hepatic, or active infectious disease including active tuberculosis infection
  • any serious medical or psychiatric AE after test infusion of MA 30mg IV (e.g. sustained SBP>200 or DBP>100; sustained pulse >(220-0.85xAge)
  • seeking treatment for MA problems at the time of the study
  • any other circumstances that, in the opinion of the investigators, would compromise participant safety and/or successful completion of the trial

Where in United States

  • UCLA Medical CenterLos Angeles, United States
  • San Francisco Department of Public HealthSan Francisco, United States
  • Substance Use Research UnitSan Francisco, United States

About the trial

What the trial wants to find out

This is a drug-drug interaction (DDI) study of mirtazapine for methamphetamine (MA) use disorder (MUD) to ensure the safety of this medication in the presence of a relevant dose of MA for people actively-using MA.

Read full original descriptionShow less

Aim 1: To determine if mirtazapine alters the cardiovascular response to IV MA.

Aim 2: To determine if the pharmacokinetics of IV MA are altered by mirtazapine administration.

Aim 3: To evaluate the above aims in the setting of concomitant administration of methadone.

This study involves two simultaneous within-subject drug-drug interaction studies, each comprised of 12 participants. A total of 24 subjects will be enrolled who have methamphetamine use disorder who will be classified into 2 groups: (Group 1: no opioids; Group 2: opioid use disorder on methadone maintenance). Subjects will be randomized to the order of mirtazapine and placebo (i.e. one-half will receive mirtazapine first, then placebo; one-half will receive placebo first, then mirtazapine).

The 2 groups in the trial

  • MirtazapineTreatment being tested

    Mirtazapine 30 mg PO daily x 4 days

    Treatment: Mirtazapine and Methamphetamine

  • PlaceboPlacebo, for comparison

    Placebo 30 mg PO Daily x 4 days

    Treatment: Methamphetamine

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 1 Safety-interaction Study of Mirtazapine for the Treatment of Methamphetamine Use Disorder
Record updated
27 September 2024